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Major allergic disease can be viewed as clinical syndromes rather than discrete disease 
entities. Emerging evidence indicates that allergic asthma includes several disease phe-
notypes. Immunological deviation toward high T helper cell type 2 cytokine levels has 
been demonstrated for a subgroup of pediatric asthma patients, and now, several novel 
monoclonal antibodies have been approved for treatment of this subgroup as a stratified 
approach of “personalized” medicine in allergy. Introduction of component-based IgE 
testing before allergen immunotherapy (AIT), i.e., testing for IgE cross-reactivity before 
initiation of AIT, has also brought stratified medicine into allergy therapy. Improved 
responder criteria, which identify treatment-responders previous to therapy, might foster 
this stratification and even individualized AIT might have an impact for tailor-made ther-
apy in the future. Furthermore, combining antibody-based treatment with AIT could help 
to establish more rapid AIT protocols even for allergens with a high risk of anaphylactic 
reactions. Efforts to advance such “personalized” medicine in pediatric allergy might be 
challenged by several issues including high costs for the health-care system, increasing 
complexity of allergy therapy, the need for physician allergy expertise, and furthermore 
ethical considerations and data safety issues.
Keywords: allergy, asthma, personalized medicine, stratified medicine, allergen immunotherapy, biologicals, 
monoclonal antibodies
inTRODUCTiOn
Over recent emerging evidence has shown that major allergic diseases represent syndromes rather 
than single disease entities (1, 2). Specifically, pediatric asthma reflects several phenotypes, which 
might reflect different mechanisms called “endotypes” (2). As a major endotype, immunological 
deviation toward high T helper cell type 2 (Th2) cytokine levels in a subpopulation of asthma 
patients has been proposed by several studies. Novel monoclonal antibodies have been demon-
strated to ameliorate disease in “Th2high” patients and other subpopulations. Here, we focus on 
antibodies interfering with Th2 cytokines (IL-4, IL-5, IL-13). A number of other antibodies such 
as anti-thymic stromal lymphopoetin have been tested but are not currently available to patients 
including children. Beyond clinical characteristics, studies on biomarkers are being developed to 
identify patient subpopulations who might benefit from novel therapy in contrast to non-responders 
(3). Such stratification strategies coined the term “stratified medicine” or “precision medicine” in 
allergy treatment. In allergy, truly individual treatment, i.e., individual composition of recombinant 
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allergens for allergen immunotherapy (AIT) is not available and 
limited by regulatory processes in many countries (4, 5). Of note, 
“personalized medicine” is considered more than “treating the 
right patient with the right drug at the right time” since every 
patient–doctor relationship includes personal aspects of disease. 
Here, “stratified medicine” will be used as the more precise term 
instead of “personalized medicine.”
“Th2high” ASTHMA
Development and market authorization of “biologicals” termed 
monoclonal antibodies is an demanding process for the manu-
facturer and also approved drugs like Omalizumab are still of 
limited use in the field. Whereas recruitment of study patients 
to fill subpopulation groups is challenging in study planning, 
approved antibodies are high priced and limit their broad accept-
ance and usage in the field. Given small patient subpopulations 
in clinical trials, the risk of failure in follow-up studies is higher 
in stratified medicine. For example, airway epithelium-derived 
protein periostin was helpful to identify asthma patients with 
high expression levels of the Th2 cytokine IL-13 (3) and applica-
tion of the anti-IL-13 maAb Lebrikizumab ameliorated asthma 
in these patients (6). Of note, application of Lebrikizumab to 
the whole asthma patient group showed little or no effect (6). 
Intriguingly, follow-up studies [LAVOLTA I and II (7)] also 
revealed conflicting data for the treatment with Lebrikizumab 
in the “Th2high” patient subgroup, and therefore, Lebrikizumab 
will not be followed up as an asthma drug by the manufacturer. 
Nevertheless, these efforts demonstrated that in allergic asthma 
patient subpopulations exist, who might benefit from a specific 
treatment whereas other patients might not. Earlier in 2016, anti-
IL-5 antibodies Bendralizumab, Mepolizumab, and Reslizumab 
were FDA approved for the treatment of the subgroup of patients 
with severe esoinophilic asthma. It is noteworthy, that when 
such studies were performed almost 15 years ago in the broader 
asthma population, few convincing effects were observed. With 
the emerging concept of stratified medicine in allergy, follow-up 
studies highlighted the importance of defining subpopulations to 
demonstrate significant effects in not all but few asthma patients 
defined by several criteria. With a focus on patients with “Th2 
high” allergic asthma several biomarkers have been proposed. 
Specificity of such “Th2 high” surrogate markers remains contro-
versial, i.e., increased blood eosinophil levels were used to define 
patients who might benefit from treatment with Dupliumab, an 
IL-4 receptor α-blocking antibody. However, also patients with 
lower blood eosinophil counts showed significant improvement 
of asthma (8). Obviously, current definitions of “Th2 high” asthma 
are difficult to use in the clinical setting. This may not just be 
due to insufficient surrogate markers for definition of “Th2 high” 
asthma but also due to significant variability of this endotype with 
discrete subtypes among patients with asthma.
FROM BenCH TO BeD AnD BACK: 
“BiOLOGiCALS” in ALLeRGY
Bringing these so-called “biologicals” into the market of major 
public health system is not only demanding for the manufacturer. 
Costs for novel antibody-based therapies frequently exceed 
several tens of thousands of Euro/US dollar per year for a 
single patient. Furthermore, defining the target population is 
still a dynamic process, since most antibodies interfere with 
key molecules (i.e., IgE, IL-4/IL-13, IL-5) in different major 
allergic diseases. Lebrikizumab was considered to be used for 
a subgroup of “Th2high” asthma patients. In fact, this will not 
be followed up. Instead, testing for atopic dermatitis comes 
into play. Similarly, Dupliumab shows high potential for atopic 
dermatitis therapy (9) even before being approved for asthma 
treatment. Omalizumab has previously been approved for treat-
ment of chronic urticaria (10)—years after market authorization 
for severe asthma patients. Collectively, identification of patients 
with highest benefit for a given drug is a dynamic process even 
in the age of companion diagnostic tests with biomarkers used 
to define subgroups.
For research, data from clinical studies with antibodies are of 
major importance. Translation of knowledge from small animal 
models is very limited and frequently used genetic knockdown 
approaches cannot easily be followed up in humans. With the 
application of highly specific antibodies, this translational “gap” 
is getting smaller. Furthermore, clinical responses to antibodies 
might help defining asthma phenotypes much better than before, 
and this asks for better design of animal models based on lessons 
learnt in the patient.
AiT: ReSPOnDeR veRSUS nOn-
ReSPOnDeR
Treating allergies by application of proteins has been success-
fully performed by AIT for several years. It is well known that 
some patients respond to AIT very well, whereas other patients 
show almost no effect above substantial placebo effects (11). In 
general, it is not just subcutaneous immunotherapy (SCIT) that 
has been proven as efficient, but also sublingual immunotherapy 
(SLIT) (12, 13). However, only a few high-quality studies have 
been published so far for children, and more studies are necessary 
to extend the number of evidence-based AIT preparations for 
SCIT or SLIT in pediatric AIT. Considered especially important 
are studies on the prevention of allergic asthma. Finally, data 
derived from study cohorts need to be translated into “real-life.” 
Introduction of component-based IgE testing has helped to iden-
tify patients with higher risk to fail or benefit in AIT, especially in 
patients with multiple allergic sensitizations, i.e., grass and birch 
pollen allergies (14). Preliminary data suggest that higher levels 
of allergen-specific IgE could be helpful to predict AIT efficacy, 
i.e., IgE levels to house dust mite in children (15). Similar progress 
has been made in venom immunotherapy (VIT) for patients 
with anaphylaxis due to Hymenoptera stings. Differentiation 
between true sensitization and cross-reactivity based on cross-
reactive carbohydrate determinants free species-specific allergens 
improved the selection of the appropriate VIT (16). Furthermore, 
patients with honey bee venom allergy and predominant Api m 
10 sensitization have an increased risk of treatment failure due to 
a lack of Api m 10 in many preparations (17). In future, prospec-
tive studies are required to confirm these results derived from 
retrospective studies.
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Further work is required to give the physician substantial 
diagnostic tests that can applied with ease to separate AIT 
responders from non-responders. Unbiased screening of bio-
material collected from clinical trials previous to approval by 
national regulatory authorities might help identification of novel 
biomarkers for detection of AIT responders beyond specific IgE 
antibodies. From a therapeutical point of view, much progress 
has been achieved in standardization of AIT products, mostly 
due to regulatory processes, i.e., approval by institutions like 
the Paul-Ehrlich Institute in Germany and novel regulations 
like the German Therapieallergene-Verordnung (18). However, 
regulatory processes have constantly to be followed up. Market 
authorization of individual AIT preparations defined by defini-
tion of individual allergic sensitization profiles, i.e., based on 
component-based IgE technology, is currently limited by regula-
tion (19). Similar to many blood-derived good manufacturing 
practice products, approval of the production process might 
replace individual product approval in the future.
Following market authorization, acceptance in the allergy 
field is required to establish stratified or even individualized 
medicine as an integral part of the daily working routine in 
allergy treatment. Expert knowledge needs to be acquired from 
the physician and continuous communication from doctors 
with their patients but also with regulatory institutions, and 
many other key players in health-care systems are warranted to 
allow sustained progress. Since many therapeutical innovations 
focus on allergic asthma in children, there is a need for more 
pediatricians with expert training in allergy and pulmonology. 
Of note, risk factors of stratified or individualized medicine 
like data safety issues and increasing costs ask for participation 
of the general population into the discussion about stratified 
medicine in a given health-care system. Regulatory institutions 
need to keep up with novel treatment options and diagnostic 
tests in allergy.
CO-ADMiniSTRATiOn OF AiT AnD 
“BiOLOGiCALS”
In the future, application of biologicals together with AIT might 
improve and extend AIT. For example, MacGinnitie and colleagues 
reported early in 2016 that application of Omalizumab in patients 
with peanut allergy allowed rapid oral desensitization with high 
doses of peanut allergen (20). It is known, that intralymphatic 
application of allergen allows much higher antigen doses in the 
lymph node than conventional biodistribution of allergen fol-
lowing subcutaneous (s.c.) injection (21). Furthermore, only few 
intralymphatic injections show similar or even faster efficacy than 
s.c. injection (22). This suggests that increasing allergen doses by 
conventional routes (s.c., per oral) might still have some potential 
for AIT optimization. Shorter protocols with higher doses of 
allergen might increase patient adherence to AIT but requires 
additional medication like Omalizumab to give protection from 
strong anaphylactic reactions. These efforts seem reasonable 
especially when novel predictive tests of AIT responders will 
allow identification of the right patient.
SUMMARY
Several novel drugs have been approved for “stratified” medicine 
in allergy and many more might follow. Treatment decision-
making will get more complex, especially if responder criteria for 
a suggested therapy are weak. As “personalized medicine” comes 
of age, several challenges need to be considered including high 
costs for health-care systems, more complex study designs due to 
difficult patient recruitment for smaller subgroups, and data safety 
considerations in the age of pharmacogenetics. Furthermore, the 
increasing complexity of allergy therapy asks for physicians with 
expertise in allergy. Treating the right patient with the right drug 
at the right time continues to be a therapeutical challenge.
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